Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcirol is a brand of cholecalciferol (Vitamin D3), a fat-soluble secosteroid essential for the regulation of calcium and phosphate homeostasis and the maintenance of bone health. It is primarily marketed in India by Cadila Pharmaceuticals and is available in various formulations, including granules in sachets, tablets, and oral solutions. As a pro-hormone, cholecalciferol is converted in the liver to 25-hydroxyvitamin D [25(OH)D] and subsequently in the kidneys to its active form, 1,25-dihydroxyvitamin D (calcitriol). This active metabolite binds to the nuclear Vitamin D receptor (VDR), promoting intestinal calcium absorption and bone mineralization. Calcirol is widely used for the treatment and prevention of vitamin D deficiency, rickets, osteomalacia, and osteoporosis, and it has been investigated for its potential benefits in critically ill patients and those with nephrotic syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Calcirol.